Physician profile
Maxwell Arons
NPI 1558718809
$1,355.70
in general payments reported to CMS, 2019-2025
21 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $129 · 2022: $78.99 · 2023: $90.47 · 2024: $336 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $183.16 | 2019-2024 | Airsupra |
| Viiv Healthcare Company | $182.24 | 2022-2025 | Apretude |
| Amgen INC. | $181.24 | 2019-2025 | Repatha, Otezla |
| Pfizer INC. | $125.44 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $120.80 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $116.45 | 2019 | |
| Novo Nordisk INC | $110.55 | 2020-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.98 | 2019-2020 | |
| Astellas Pharma US INC | $54.71 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $37.24 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.44 | 2025 | Xifaxan |
| Lilly USA, LLC | $20.32 | 2025 | Zepbound |
| Adlon Therapeutics L.P. | $19.71 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.39 | 2025 | Gvoke Hypopen |
| Collegium Pharmaceutical, INC. | $19.26 | 2025 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $16.99 | 2025 | Immunocap |
| Neos Therapeutics, Lp | $15.87 | 2019 | |
| Glaxosmithkline, LLC. | $15.85 | 2020 | |
| Esperion Therapeutics, INC. | $13.85 | 2025 | Nexletol |
| Cranial Technologies, INC | $12.26 | 2019 | |
| Merck Sharp & Dohme LLC | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxwell Arons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.